New research links glucosamine, taken by over 40 million people for arthritis relief, to a 25% higher risk of dementia progression in those with early cognitive decline.
The findings, published June 9 in Nature Metabolism, suggest a metabolic pathway in Alzheimer’s that could become a treatment target—but regulatory oversight remains a critical gap.
What’s next? Experts warn against stopping glucosamine abruptly, but urge patients with memory concerns to discuss alternatives with their doctors.
The Glucosamine Paradox: How a Joint Pain Remedy May Worsen Alzheimer’s
A widely used supplement for joint pain—glucosamine—has been linked to faster progression of Alzheimer’s disease in a study published this month in Nature Metabolism. Researchers at the University of Florida found that people with mild cognitive impairment (MCI) who took glucosamine were 25% more likely to develop full-blown Alzheimer’s within five years compared to those who didn’t. For those already diagnosed with Alzheimer’s, glucosamine use was associated with a 25% higher risk of death within the same period.
The findings are striking because glucosamine is taken by over 40 million Americans annually for arthritis relief, with many assuming it’s harmless. But the study suggests it may be accelerating a metabolic process in the brain—hyperglycosylation—that contributes to Alzheimer’s progression.
“A lot of these people actively take an over-the-counter supplement that could be making their disease progression worse,” said Ramon Sun, Ph.D., director of the Center for Advanced Spatial Biomolecule Research at the University of Florida’s McKnight Brain Institute, in a statement to ScienceDaily. Sun’s team analyzed anonymized health records from over 65,000 patients with Alzheimer’s or MCI, alongside advanced imaging of brain tissue and mouse models.
How Glucosamine May Be Accelerating Alzheimer’s
The study identifies a specific biological mechanism: glucosamine appears to fuel an overactive sugar-tagging process in the brain called hyperglycosylation. Normally, proteins in brain cells carry short sugar chains (N-glycans) that help them fold correctly and interact with other proteins. But in Alzheimer’s, these sugar chains pile up abnormally, disrupting protein function and contributing to memory loss and cell death.
Using advanced spatial metabolomics—an imaging technique that maps thousands of molecules in brain tissue—the researchers found that glucosamine may exacerbate this process. In mouse models of Alzheimer’s, blocking the enzyme that produces glucosamine-like sugars improved memory symptoms, while feeding glucosamine made memory loss worse. Healthy mice showed no effect.
“Our results suggest that altered metabolism is a significant contributor to Alzheimer’s progression,” Sun told UF Health. “Addressing the metabolic defect could be an important complement to approaches focused on Alzheimer’s plaques and tangles.”
The discovery builds on earlier research showing that sugar metabolism plays a role in Alzheimer’s. A 2024 study in Nature found that glycans—sugar molecules—accumulate in brain tissue as the disease progresses. The new work suggests glucosamine may be worsening this process by feeding into the same pathways.
Why This Matters: The Regulatory Gap for Over-the-Counter Supplements
Here’s the catch: glucosamine is classified as a dietary supplement, not a drug. That means it’s not subject to the same rigorous testing as prescription medications. The Food and Drug Administration (FDA) regulates supplements differently—manufacturers don’t need to prove safety or efficacy before selling them.
“The FDA classifies glucosamine as a dietary supplement, not a prescription drug,” noted the lead author in ScienceAlert. “As a result, anyone can buy it over the counter without seeing a doctor.”
This lack of oversight means millions of Americans—particularly older adults prone to joint pain—may be unknowingly taking a supplement that could accelerate cognitive decline. The study’s authors emphasize that their findings are associative, not causative, and that more research is needed. But the results are provocative enough to warrant caution.
“While it’s an association and not proof of causality, it does raise an important clinical question that now deserves much more attention,” Sun said in a statement to Nature. The study’s lead author, Dr. Yi Guo, added that the findings highlight the need for better monitoring of metabolic pathways in Alzheimer’s treatment.
What the Data Shows: Key Findings from the Study
The study analyzed data from 24,000 patients with Alzheimer’s and 41,000 with mild cognitive impairment (MCI), comparing those who took glucosamine to those who didn’t.
- 25% higher risk of progressing from MCI to Alzheimer’s in glucosamine users.
- 25% increased mortality risk among Alzheimer’s patients taking glucosamine.
- 8% of Alzheimer’s and MCI patients in the study reported taking glucosamine.
- No significant effect on healthy mice, suggesting the impact is specific to Alzheimer’s-related metabolic dysfunction.
The study also used advanced imaging to show that glucosamine may interact with a protein and sugar-tagging pathway that’s already overactive in Alzheimer’s brains. This pathway could become a new target for treatments, according to the researchers.
What Happens Next? Expert Reactions and Patient Advice
The study’s authors stress that their findings are preliminary and require confirmation in clinical trials. However, they urge caution—especially for older adults who may be taking glucosamine for joint pain while also showing early signs of cognitive decline.
“A lot of these people actively take an over-the-counter supplement that could be making their disease progression worse,” Sun reiterated. “This is not a call to panic, but it is a call to be informed.”
Experts recommend that patients with memory concerns discuss their supplement use with their doctors. While stopping glucosamine abruptly could have its own risks (such as joint pain flare-ups), alternatives like chondroitin sulfate, turmeric, or physical therapy may be safer options for joint health. Some doctors may also recommend monitoring metabolic markers in blood tests for those at risk of Alzheimer’s.
The study also raises broader questions about how dietary supplements are regulated. With over 7 million Americans living with Alzheimer’s and millions more at risk, the findings underscore the need for better oversight of supplements that may interact with neurological diseases.
The Bigger Picture: Metabolic Targets in Alzheimer’s Treatment
This study is part of a growing body of research suggesting that metabolic dysfunction—particularly in sugar and lipid processing—plays a key role in Alzheimer’s. Traditional treatments have focused on amyloid plaques and tau tangles, but emerging evidence points to metabolic pathways as equally important targets.
“Addressing the metabolic defect could be an important complement to approaches focused on Alzheimer’s plaques and tangles,” Sun said. The team’s spatial metabolomics technology allowed them to identify thousands of molecules in brain tissue, revealing intricate pathways that could be disrupted by glucosamine.
If confirmed, this research could open new avenues for treatment—possibly by targeting the sugar-tagging pathways that glucosamine appears to influence. However, clinical trials will be needed to determine whether blocking these pathways could slow or reverse cognitive decline.
What Should You Do If You Take Glucosamine?
- Consult your doctor before making any changes, especially if you have early memory concerns.
- Discuss alternative joint pain remedies, such as physical therapy, anti-inflammatory foods, or other supplements like chondroitin.
- Monitor for early signs of cognitive decline, such as memory lapses or difficulty with familiar tasks.
- Ask about metabolic testing if you’re at high risk for Alzheimer’s—some doctors may recommend blood tests to assess sugar and lipid metabolism.
Remember: this study does not prove that glucosamine causes Alzheimer’s, but it does suggest a strong association. The safest approach is to stay informed and work with your healthcare provider to make decisions tailored to your individual health needs.
For now, the takeaway is clear: if you’re taking glucosamine and have concerns about memory or cognitive function, it’s worth having a conversation with your doctor. The supplement may not be as harmless as once thought—and the stakes for Alzheimer’s patients couldn’t be higher.
As Sun put it: “This technology allows us to examine thousands and thousands of molecules created when the body breaks down food or drugs and to uncover intricate pathways that otherwise would stay hidden.” The next step? More research—and better regulation—to protect those most at risk.
Find more reporting in our Health section.
